SCHEMBL233368

SCHEMBL233368

COC(=O)C12CC3CC(C1)C(NC(=O)C(C)(C)N1CCNCC1)C(C3)C2

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 20/20 0.54
HSD11B2 P80365 11/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3051372 0.88 HSD11B1 (0.56) HSD11B1HSD11B2
SCHEMBL5243064 0.88 HSD11B1 (0.56) HSD11B1HSD11B2
SCHEMBL230588 0.85 HSD11B1 (0.53) HSD11B1HSD11B2
SCHEMBL233142 0.82 HSD11B1 (0.50) HSD11B1HSD11B2
SCHEMBL231901 0.82 HSD11B1 (0.52) HSD11B1HSD11B2
SCHEMBL232118 0.79 HSD11B1 (0.52) HSD11B1HSD11B2
SCHEMBL16666656 0.79 HSD11B1 (0.52) HSD11B1HSD11B2
SCHEMBL19529479 0.78 HSD11B1 (0.48) HSD11B1HSD11B2
Hydrochloric Acid SCHEMBL16666654 0.78 HSD11B1 (0.51) HSD11B1HSD11B2
SCHEMBL15899732 0.78 HSD11B1 (0.45) HSD11B1HSD11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004206-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBVIE INC. 2012-01-05 US disclosed
EP-2345640-A1 Adamantyl- acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7880001-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2011-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004206-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD11B2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.